Overview

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

Status:
Completed
Trial end date:
2019-11-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Treatments:
Tilavonemab